Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2014 Apr;28(2):355-74. doi: 10.1016/j.hoc.2013.11.011. Epub 2014 Jan 18.

Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Author information

1
Division of Hematology Oncology, Davis School of Medicine, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA.
2
Division of Hematology Oncology, Davis School of Medicine, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA; UC Davis Clinical and Translational Sciences Center, VA Northern California Health Care System, Sacramento, CA, USA. Electronic address: ted.wun@ucdmc.ucdavis.edu.

Abstract

Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.

KEYWORDS:

Anti-platelets; Anticoagulants; Hypercoagulable; Sickle cell; Thromboembolism

PMID:
24589271
PMCID:
PMC3984936
DOI:
10.1016/j.hoc.2013.11.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center